This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
AstraZeneca's (AZN) Imfinzi/Imjudo Combo Gets Another FDA Nod
by Zacks Equity Research
AstraZeneca (AZN) gets its second FDA approval for the Imfinzi+Imjudo combo in non-small cell lung cancer (NSCLC) indication.
Sanofi (SNY), Regeneron Dupixent Gets CHMP Nod for Skin Disease
by Zacks Equity Research
The CHMP recommends approval of Sanofi's (SNY) Dupixent for the treatment of prurigo nodularis, a chronic inflammatory skin disease.
Jazz's (JAZZ) Q3 Earnings Beat Estimates, New Drugs Drive Sales
by Zacks Equity Research
Jazz's Q3 earnings and sales beat expectations on strong demand for new drugs and drugs added with the GW Pharmaceuticals acquisition. The company raises the mid-point of its 2022 sales guidance.
AstraZeneca's (AZN) Q3 Earnings Beat, EPS Growth View Up
by Zacks Equity Research
AstraZeneca (AZN) beats third-quarter estimates for earnings while sales come in line. AZN raises its 2022 earnings growth guidance, keeping its sales forecast unchanged.
Reata (RETA) Q3 Earnings Beat, Stock Up on Pipeline Updates
by Zacks Equity Research
Reata (RETA) reports a narrower-than-expected loss in the third quarter. Stock rises after RETA states that the FDA did not request additional data on the NDA for omaveloxolone in Friedreich's ataxia.
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Here is Why Growth Investors Should Buy Vertex (VRTX) Now
by Zacks Equity Research
Vertex (VRTX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Perrigo (PRGO) Lags on Q3 Earnings & Sales, Lowers '22 EPS View
by Zacks Equity Research
Perrigo (PRGO) reports dismal third-quarter 2022 results. Unfavorable currency movements force management to lower earnings outlook for 2022. Shares down.
Puma Biotech (PBYI) Q3 Earnings Top, Nerlynx Sales View Up
by Zacks Equity Research
Puma Biotech (PBYI) beats earnings and revenue estimates for third-quarter 2022. It increases product revenue guidance for full-year 2022 to reflect improving demand trends for Nerlynx in the United States.
TEVA Misses on Q3 Earnings, Cuts 2022 Sales View, Stock Down
by Zacks Equity Research
TEVA reports dismal Q3 results, missing estimates for both earnings and sales. It slightly lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact.
CRISPR Therapeutics (CRSP) Q3 Earnings Top, Sales Lag Estimates
by Zacks Equity Research
CRISPR Therapeutics (CRSP) third-quarter 2022 loss is narrower than expected, while sales miss estimates.
What Awaits Lantheus Holdings (LNTH) This Earnings Season?
by Zacks Equity Research
Lantheus Holdings' (LNTH) third-quarter results are likely to reflect solid top line results on the back of robust product adoption.
Vertex (VRTX) Beats on Q3 Earnings, Ups 2022 Sales Guidance
by Zacks Equity Research
Vertex Pharmaceuticals' (VRTX) third-quarter 2022 earnings and sales beat estimates. VRTX also raises its revenue guidance for 2022. The stock rises in the after-market trading.
Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Vertex (VRTX) delivered earnings and revenue surprises of 8.67% and 4.69%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Drug/Biotech Stocks' Q3 Earnings on Oct 27: MRK, GILD & More
by Zacks Equity Research
Let's analyze how the four pharma/drug/biotech companies are placed before the quarterly earnings release on Oct 27.
Vertex (VRTX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
On Vertex Pharmaceuticals' (VRTX) Q3 earnings call, investors' focus will likely be on the sales performance of its cystic fibrosis medicines and updates on its non-CF pipeline candidates.
CRISPR (CRSP) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
CRSIPR Therapeutics (CRSP) is expected to update its pipeline candidates, specifically exa-cel, its lead candidate, in its third-quarter earnings.
Earnings Preview: Ultragenyx (RARE) Q3 Earnings Expected to Decline
by Zacks Equity Research
Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vertex Pharmaceuticals (VRTX) Stock Moves -0.64%: What You Should Know
by Zacks Equity Research
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $290.16, marking a -0.64% move from the previous day.
Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Eli Lilly (LLY) to Buy Hearing Loss Gene Therapy Maker Akouos
by Zacks Equity Research
Lilly (LLY) is set to acquire all the outstanding shares of Akouos for approximately $487 million plus a contingent value right for an aggregate amount up to approximately $610 million.
Vertex Pharmaceuticals (VRTX) Stock Moves -1.12%: What You Should Know
by Zacks Equity Research
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $293.21, marking a -1.12% move from the previous day.
3 Medical Stocks to Buy in 2022 for Long-Term Resilience
by Indrajit Bandyopadhyay
Here we discuss two Medical companies, VRTX, ISRG and AMN, that may prove to be wealth creators for investors over the long term on the back of their strong fundamentals.